{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:48:52Z","timestamp":1785577732116,"version":"3.56.0"},"reference-count":102,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T00:00:00Z","timestamp":1527120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR-N006372-1"],"award-info":[{"award-number":["MR-N006372-1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Influenza-virus-mediated disease can be associated with high levels of morbidity and mortality, particularly in younger children and older adults. Vaccination is the primary intervention used to curb influenza virus infection, and the WHO recommends immunization for at-risk individuals to mitigate disease. Unfortunately, influenza vaccine composition needs to be updated annually due to antigenic shift and drift in the viral immunogen hemagglutinin (HA). There are a number of alternate vaccination strategies in current development which may circumvent the need for annual re-vaccination, including new platform technologies such as viral-vectored vaccines. We discuss the different vectored vaccines that have been or are currently in clinical trials, with a forward-looking focus on immunogens that may be protective against seasonal and pandemic influenza infection, in the context of viral-vectored vaccines. We also discuss future perspectives and limitations in the field that will need to be addressed before new vaccines can significantly impact disease levels.<\/jats:p>","DOI":"10.3390\/vaccines6020029","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T07:54:01Z","timestamp":1527148441000},"page":"29","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Clinical Advances in Viral-Vectored Influenza Vaccines"],"prefix":"10.3390","volume":"6","author":[{"given":"Sarah","family":"Sebastian","sequence":"first","affiliation":[{"name":"The Jenner Institute, University of Oxford, Old Road Campus Research Building, Headington, Oxford OX3 DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Lambe","sequence":"additional","affiliation":[{"name":"The Jenner Institute, University of Oxford, Old Road Campus Research Building, Headington, Oxford OX3 DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,5,24]]},"reference":[{"key":"ref_1","unstructured":"Iuliano, A.D., Roguski, K.M., Chang, H.H., Muscatello, D.J., Palekar, R., Tempia, S., Cohen, C., Gran, J.M., Schanzer, D., and Cowling, B.J. (2017). Estimates of global seasonal influenza-associated respiratory mortality: A modelling study. Lancet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1016\/j.vaccine.2007.03.046","article-title":"The annual impact of seasonal influenza in the US: Measuring disease burden and costs","volume":"25","author":"Molinari","year":"2007","journal-title":"Vaccine"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1353\/bhm.2002.0022","article-title":"Updating the accounts: Global mortality of the 1918\u20131920 \u201cSpanish\u201d influenza pandemic","volume":"76","author":"Johnson","year":"2002","journal-title":"Bull. Hist. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fmicb.2018.00123","article-title":"Universal Vaccines and Vaccine Platforms to Protect against Influenza Viruses in Humans and Agriculture","volume":"9","author":"Rajao","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1016\/j.vaccine.2007.07.027","article-title":"Influenza vaccine: The challenge of antigenic drift","volume":"25","author":"Carrat","year":"2007","journal-title":"Vaccine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1016\/j.vaccine.2009.06.032","article-title":"Influenza control in the 21st century: Optimizing protection of older adults","volume":"27","author":"Monto","year":"2009","journal-title":"Vaccine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"12578","DOI":"10.1073\/pnas.1712377114","article-title":"Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains","volume":"114","author":"Zost","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"12387","DOI":"10.1128\/JVI.05570-11","article-title":"Analysis of influenza virus hemagglutinin receptor binding mutants with limited receptor recognition properties and conditional replication characteristics","volume":"85","author":"Bradley","year":"2011","journal-title":"J. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.4049\/jimmunol.0900398","article-title":"Original Antigenic Sin Responses to Influenza Viruses","volume":"183","author":"Kim","year":"2009","journal-title":"J. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1126\/science.1097211","article-title":"Mapping the antigenic and genetic evolution of influenza virus","volume":"305","author":"Smith","year":"2004","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/ni1343","article-title":"Influenza and the challenge for immunology","volume":"7","author":"Doherty","year":"2006","journal-title":"Nat. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1016\/j.vaccine.2016.03.085","article-title":"Universal influenza vaccines: Shifting to better vaccines","volume":"34","author":"Tsvetnitsky","year":"2016","journal-title":"Vaccine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJM198307073090103","article-title":"Cytotoxic T-cell immunity to influenza","volume":"309","author":"McMichael","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nm.2612","article-title":"Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans","volume":"18","author":"Wilkinson","year":"2012","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/nm.3350","article-title":"Cellular immune correlates of protection against symptomatic pandemic influenza","volume":"19","author":"Sridhar","year":"2013","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1164\/rccm.201411-1988OC","article-title":"Natural T Cell-mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study","volume":"191","author":"Hayward","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6527","DOI":"10.1128\/JVI.00519-10","article-title":"Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus","volume":"84","author":"Tu","year":"2010","journal-title":"J. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8682","DOI":"10.1128\/JVI.72.11.8682-8689.1998","article-title":"Human cytotoxic T-lymphocyte repertoire to influenza A viruses","volume":"72","author":"Jameson","year":"1998","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Agrati, C., Castilletti, C., Cimini, E., Lapa, D., Quartu, S., Caglioti, C., Lanini, S., Cattoli, G., Martini, F., and Ippolito, G. (2014). Cellular and humoral cross-immunity against two H3N2v influenza strains in presumably unexposed healthy and HIV-infected subjects. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0105651"},{"key":"ref_20","first-page":"3478","article-title":"Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals","volume":"118","author":"Lee","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1073\/pnas.1322229111","article-title":"Preexisting CD8+ T-cell immunity to the H7N9 influenza A virus varies across ethnicities","volume":"111","author":"Grant","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.coi.2016.05.014","article-title":"Viral vectors as vaccine platforms: from immunogenicity to impact","volume":"41","author":"Ewer","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/CJI.0b013e3181f5dac7","article-title":"Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients","volume":"33","author":"Harrop","year":"2010","journal-title":"J. Immunother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14760584.2017.1335201","article-title":"A recombinant live attenuated tetravalent vaccine for the prevention of dengue","volume":"16","author":"Guy","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1586\/erv.10.139","article-title":"IMOJEV((R)): A Yellow fever virus-based novel Japanese encephalitis vaccine","volume":"9","author":"Appaiahgari","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/S2214-109X(16)30367-9","article-title":"Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: Final report of a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"5","author":"Li","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/21645515.2016.1238535","article-title":"Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I\/II trial in healthy adults in Russia","volume":"13","author":"Dolzhikova","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1080\/21645515.2016.1210729","article-title":"Viral vector-based influenza vaccines","volume":"12","author":"Rimmelzwaan","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.3390\/v6062392","article-title":"Alphavirus-based vaccines","volume":"6","author":"Lundstrom","year":"2014","journal-title":"Viruses"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1586\/14760584.2015.979798","article-title":"RNA-based viral vectors","volume":"14","author":"Mogler","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"ref_31","unstructured":"AlphaVax (2018, April 01). AlphaVax Clinical Experience. Available online: https:\/\/www.alphavax.com\/clinical-experience.html."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/imm.12829","article-title":"Novel viral vectors in infectious diseases","volume":"153","author":"Humphreys","year":"2018","journal-title":"Immunology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.vaccine.2004.07.043","article-title":"Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans","volume":"23","author":"Shi","year":"2005","journal-title":"Vaccine"},{"key":"ref_34","unstructured":"(2018, February 01). Single-Ascending-Dose Study of the Safety and Immunogenicity of NasoVAX, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03232567."},{"key":"ref_35","unstructured":"(2018, February 01). Safety and Immunogenicity Study of Adenovirus-Vectored, Intranasal Pandemic Influenza Vaccine, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT00755703."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.vaccine.2013.01.023","article-title":"Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-gamma T cell responses in humans","volume":"31","author":"Peters","year":"2013","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S1473-3099(15)00266-2","article-title":"High titre neutralising antibodies to influenza after oral tablet immunisation: A phase 1, randomised, placebo-controlled trial","volume":"15","author":"Liebowitz","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"37295","DOI":"10.1038\/srep37295","article-title":"Systemic and mucosal immune responses following oral adenoviral delivery of influenza vaccine to the human intestine by radio controlled capsule","volume":"6","author":"Kim","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_39","unstructured":"Vaxart (2018, April 01). Vaxart News Releases. Available online: http:\/\/vaxart.com\/NRfiles\/VaxartAnnouncesReducedInfluenzaInPhase2InfluenzaChallenge013118.pdf."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/cid\/ciu507","article-title":"Dramatic decline of respiratory illness among US military recruits after the renewed use of adenovirus vaccines","volume":"59","author":"Radin","year":"2014","journal-title":"Clin Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S1473-3099(12)70345-6","article-title":"Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: A randomised, double-blind, placebo-controlled, phase 1 study","volume":"13","author":"Gurwith","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"ref_42","unstructured":"(2018, February 01). Intranasal AD4-H5-VTN as an Adenovirus Vaccine, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT01806909."},{"key":"ref_43","unstructured":"(2018, February 01). Experimental AD4-H5-VTN Vaccine in Healthy Volunteers, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT01443936."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Dicks, M.D., Spencer, A.J., Edwards, N.J., Wadell, G., Bojang, K., Gilbert, S.C., Hill, A.V., and Cottingham, M.G. (2012). A novel chimpanzee adenovirus vector with low human seroprevalence: Improved systems for vector derivation and comparative immunogenicity. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0040385"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2013.284","article-title":"Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ebiom.2018.02.011","article-title":"Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults","volume":"29","author":"Coughlan","year":"2018","journal-title":"EBioMedicine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF01641272","article-title":"Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA","volume":"1","author":"Mayr","year":"1975","journal-title":"Infection"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"ofv040","DOI":"10.1093\/ofid\/ofv040","article-title":"Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial","volume":"2","author":"Overton","year":"2015","journal-title":"Open Forum Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1016\/j.vaccine.2013.03.020","article-title":"Clinical development of Modified Vaccinia virus Ankara vaccines","volume":"31","author":"Gilbert","year":"2013","journal-title":"Vaccine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciq015","article-title":"Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1","volume":"52","author":"Berthoud","year":"2011","journal-title":"Clin Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Powell, T.J., Peng, Y., Berthoud, T.K., Blais, M.E., Lillie, P.J., Hill, A.V., Rowland-Jones, S.L., McMichael, A.J., Gilbert, S.C., and Dong, T. (2013). Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0062778"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/cid\/cis327","article-title":"Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans","volume":"55","author":"Lillie","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Antrobus, R.D., Lillie, P.J., Berthoud, T.K., Spencer, A.J., McLaren, J.E., Ladell, K., Lambe, T., Milicic, A., Price, D.A., and Hill, A.V. (2012). A T cell-inducing influenza vaccine for the elderly: Safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0048322"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1002\/eji.201242922","article-title":"Improved adjuvanting of seasonal influenza vaccines: Preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine","volume":"43","author":"Mullarkey","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/mt.2013.162","article-title":"Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_56","unstructured":"(2018, February 01). Improved Novel VaccIne CombinaTion InflUenza Study, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03300362."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1473-3099(14)70963-6","article-title":"Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: A randomised, double-blind phase 1\/2a clinical trial","volume":"14","author":"Kreijtz","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3201\/eid2106.150021","article-title":"Induction of influenza (H5N8) antibodies by modified vaccinia virus Ankara H5N1 vaccine","volume":"21","author":"Bestebroer","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Yoshida, R., Igarashi, M., Ozaki, H., Kishida, N., Tomabechi, D., Kida, H., Ito, K., and Takada, A. (2009). Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000350"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"17040","DOI":"10.1073\/pnas.1212371109","article-title":"Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity","volume":"109","author":"Lee","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nature11414","article-title":"Cross-neutralization of influenza A viruses mediated by a single antibody loop","volume":"489","author":"Ekiert","year":"2012","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"14216","DOI":"10.1073\/pnas.1111497108","article-title":"Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin","volume":"108","author":"Whittle","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.cell.2015.04.028","article-title":"Viral receptor-binding site antibodies with diverse germline origins","volume":"161","author":"Schmidt","year":"2015","journal-title":"Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1073\/pnas.1218256109","article-title":"Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody","volume":"110","author":"Schmidt","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e01850-17","DOI":"10.1128\/JVI.01850-17","article-title":"Structural Insight into a Human Neutralizing Antibody against Influenza Virus H7N9","volume":"92","author":"Chen","year":"2018","journal-title":"J. Virol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMoa0906453","article-title":"Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus","volume":"361","author":"Hancock","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1084\/jem.20101352","article-title":"Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection","volume":"208","author":"Wrammert","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1128\/JVI.03509-12","article-title":"H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice","volume":"87","author":"Margine","year":"2013","journal-title":"J. Virol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/infdis\/jis652","article-title":"1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans","volume":"207","author":"Miller","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3389\/fimmu.2012.00087","article-title":"Pandemic H1N1 Influenza Infection and Vaccination in Humans Induces Cross-Protective Antibodies that Target the Hemagglutinin Stem","volume":"3","author":"Thomson","year":"2012","journal-title":"Front. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/cid\/cir121","article-title":"Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies","volume":"52","author":"Sui","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/infdis\/jiw608","article-title":"Induction of Broadly Cross-Reactive Stalk-Specific Antibody Responses to Influenza Group 1 and Group 2 Hemagglutinins by Natural H7N9 Virus Infection in Humans","volume":"215","author":"Liu","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1128\/JVI.03099-14","article-title":"Broadly neutralizing anti-influenza virus antibodies: Enhancement of neutralizing potency in polyclonal mixtures and IgA backbones","volume":"89","author":"He","year":"2015","journal-title":"J. Virol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.it.2017.08.003","article-title":"From Original Antigenic Sin to the Universal Influenza Virus Vaccine","volume":"39","author":"Henry","year":"2018","journal-title":"Trends Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/14760584.2017.1299576","article-title":"Strategies to induce broadly protective antibody responses to viral glycoproteins","volume":"16","author":"Krammer","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.coi.2016.05.012","article-title":"Heads, stalks and everything else: How can antibodies eradicate influenza as a human disease?","volume":"42","author":"Neu","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"ref_77","unstructured":"(2018, February 01). Safety and Immunogenicity of a Live-Attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03300050."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nm.3927","article-title":"Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection","volume":"21","author":"Yassine","year":"2015","journal-title":"Nat. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1126\/science.aac7263","article-title":"A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen","volume":"349","author":"Impagliazzo","year":"2015","journal-title":"Science"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature12202","article-title":"Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies","volume":"499","author":"Kanekiyo","year":"2013","journal-title":"Nature"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/infdis\/jiv018","article-title":"Human Influenza A Virus-Specific CD8+ T-Cell Response Is Long-lived","volume":"212","author":"Hillaire","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Angeletti, D., and Yewdell, J.W. (2017). Is It Possible to Develop a \u201cUniversal\u201d Influenza Virus Vaccine? Outflanking Antibody Immunodominance on the Road to Universal Influenza Vaccination. Cold Spring Harb. Perspect. Biol.","DOI":"10.1101\/cshperspect.a028852"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Castilla, J., Martinez-Baz, I., Martinez-Artola, V., Reina, G., Pozo, F., Garcia Cenoz, M., Guevara, M., Moran, J., Irisarri, F., and Arriazu, M. (2013). Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011\/12. Euro Surveill., 18.","DOI":"10.2807\/ese.18.05.20388-en"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Kissling, E., Nunes, B., Robertson, C., Valenciano, M., Reuss, A., Larrauri, A., Cohen, J.M., Oroszi, B., Rizzo, C., and Machado, A. (2016). I-MOVE multicentre case-control study 2010\/11 to 2014\/15: Is there within-season waning of influenza type\/subtype vaccine effectiveness with increasing time since vaccination?. Euro Surveill., 21.","DOI":"10.2807\/1560-7917.ES.2016.21.16.30201"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/mi.2014.133","article-title":"Antibody-targeted vaccination to lung dendritic cells generates tissue-resident memory CD8 T cells that are highly protective against influenza virus infection","volume":"8","author":"Wakim","year":"2015","journal-title":"Mucosal. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.4049\/jimmunol.1501702","article-title":"Tissue Distribution of Memory T and B Cells in Rhesus Monkeys following Influenza A Infection","volume":"195","author":"Pichyangkul","year":"2015","journal-title":"J. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Zens, K.D., Chen, J.K., and Farber, D.L. (2016). Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection. JCI Insight, 1.","DOI":"10.1172\/jci.insight.85832"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1172\/JCI96957","article-title":"Influenza-specific lung-resident memory T cells are proliferative and polyfunctional and maintain diverse TCR profiles","volume":"128","author":"Pizzolla","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1016\/j.celrep.2017.08.078","article-title":"Human Tissue-Resident Memory T Cells Are Defined by Core Transcriptional and Functional Signatures in Lymphoid and Mucosal Sites","volume":"20","author":"Kumar","year":"2017","journal-title":"Cell Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.immuni.2018.01.007","article-title":"Human T Cell Development, Localization, and Function throughout Life","volume":"48","author":"Kumar","year":"2018","journal-title":"Immunity"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1084\/jem.146.3.673","article-title":"Immunologic recognition of influenza virus-infected cells. II. Expression of influenza A matrix protein on the infected cell surface and its role in recognition by cross-reactive cytotoxic T cells","volume":"146","author":"Braciale","year":"1977","journal-title":"J. Exp. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cell.2018.03.030","article-title":"Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies","volume":"173","author":"Chen","year":"2018","journal-title":"Cell"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.coviro.2016.08.015","article-title":"Corrigendum to \u2018Human influenza viruses and CD8+ T cell responses\u2019","volume":"19","author":"Grant","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"12599","DOI":"10.1073\/pnas.1007270107","article-title":"Cross-reactive CD8+ T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses","volume":"107","author":"Gras","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"9178","DOI":"10.1073\/pnas.1105624108","article-title":"Systematic identification of immunodominant CD8+ T-cell responses to influenza A virus in HLA-A2 individuals","volume":"108","author":"Wu","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"294ra105","DOI":"10.1126\/scitranslmed.aab2354","article-title":"Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2","volume":"7","author":"Ahmed","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_97","unstructured":"(2018, February 01). A Follow-On Study with an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT01403155."},{"key":"ref_98","unstructured":"(2018, February 01). Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT00819013."},{"key":"ref_99","unstructured":"(2018, February 01). Comparative Safety and Immunogenicity of 1.0 \u00b5g Intramuscular (i.m.) and 2.0 \u00b5g Subcutaneous (s.c.) Dosing with VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT00921947."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/CVI.00098-15","article-title":"A Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans","volume":"22","author":"Pleguezuelos","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e6339","DOI":"10.1097\/MD.0000000000006339","article-title":"Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: Phase IIb study protocol","volume":"96","author":"Liu","year":"2017","journal-title":"Medicine"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Van Doorn, E., Pleguezuelos, O., Liu, H., Fernandez, A., Bannister, R., Stoloff, G., Oftung, F., Norley, S., Huckriede, A., and Frijlink, H.W. (2017). Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: Study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial. BMC Infect. Dis., 17.","DOI":"10.1186\/s12879-017-2341-9"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/6\/2\/29\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:05:44Z","timestamp":1760195144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/6\/2\/29"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,24]]},"references-count":102,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,6]]}},"alternative-id":["vaccines6020029"],"URL":"https:\/\/doi.org\/10.3390\/vaccines6020029","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,24]]}}}